ArticleScientific reports2025
Combined albumin and CEA improve prognostic prediction in resectable gastric cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prognostic Value of the Gustave Roussy Immune Score in Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant FLOT Chemotherapy: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Prognostic Value of Albumin-to-CEA Ratio in Metastatic Colorectal Cancer: A Retrospective Study.Biomedicines · 2026Article
- The preoperative albumin-to-carcinoembryonic antigen ratio (ACR) predicts prognosis and facilitates risk stratification in gastric cancer: a retrospective cohort study.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preoperative high levels of serum carcinoembryonic antigen (CEA) and low levels of albumin (ALB) are closely related to poor prognosis among patients with gastric cancer. This study aims to determine the prognostic value of preoperative serum ALB plus CEA levels as a new biomarker in patients with resectable gastric cancer. This retrospective cohort study included 329 patients with gastric cancer. The optimal cutoff values of ALB and CEA were 4.77 ng/mL and 41.47 g/L, respectively. Patients were stratified into three groups based on these cutoff values: ALB-CEA = 0 (ALB > 41.47 g/L and CEA ≤ 4.77 ng/mL), ALB-CEA = 1 (ALB ≤ 41.47 g/L or CEA > 4.77 ng/mL), and ALB-CEA = 2 (ALB ≤ 41.47 g/L and CEA > 4.77 ng/mL). Kaplan-Meier curve and Cox proportional model were used to determine the predictive effect of the biomarker on the overall survival of patients in the training and validation sets. ALB-CEA had a larger area under the curve than ALB or CEA alone (0.703, 0.671, 0.635 in the validation set; 0.776, 0.694, 0.616 in the validation set respectively). The Kaplan-Meier curve revealed that higher ALB-CEA scores were indicative of lower survival rates (p < 0.001). Additionally, the multivariate analysis revealed that ALB-CEA was an independent risk factor for poor prognosis in patients with gastric cancer (p < 0.05). Preoperative ALB-CEA may be a new biomarker for predicting the prognosis of patients with gastric cancer. For those patients with higher preoperative ALB-CEA scores, more extensive postoperative follow-up should be performed to detect tumor progression early and intervene in time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.